Evidence map›Paper›PMID 41116264›Full record

ArticleEndocrine, metabolic & immune disorders drug targets2026

Buzhong Yiqi Decoction Regulates Th17 Cells Differentiation in Autoimmune Thyroiditis through PTEN/AKT-immunometabolism Axis.

Jiayun Li, Zhuo Zhao, Donglin Liu, Yue Luo, Feng-Yi Guo, Zhi-Min Wang, Nan Song, Ziyu Liu, Xiao Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiayun LiThe Second Clinic College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110847, China.
Zhuo ZhaoThe Second Clinic College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110847, China.
Donglin LiuThe Second Clinic College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110847, China.
Yue LuoThe Second Clinic College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110847, China.
Feng-Yi GuoThe Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110034, China.
Zhi-Min WangDepartment of Endcocrinology, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning110032, China.
Nan SongThe Second Clinic College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110847, China.
Ziyu LiuThe Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110034, China.
Xiao YangThe Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110034, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAutoimmune thyroiditis (AIT), a prevalent autoimmune disorder, can severely impair patients' quality of life when progressing to hypothyroidism. This investigation seeks to systematically evaluate the therapeutic efficacy of Buzhong Yiqi Decoction (BZYQ) against iodine-induced AIT while elucidating its underlying molecular mechanisms.

methodsNOD.H-2

resultsBZYQ reduced thyroid structural damage and lymphocytic infiltration in AIT mice, accompanied by significant reductions in serum TGAb and TPOAb levels. Notably, BZYQ modulated glycolysis to decrease lactate levels and the proportion of Th17 cells. Mechanistically, BZYQ upregulated PTEN expression to suppress downstream p-PI3K, p-AKT, GLUT1, HK2, PKM2, and LDHA expression, thereby achieving regulation of immunometabolic pathways. DISCUSSION: This study provides experimental evidence for broadening the modern clinical applications of this classical formula. However, the related mechanisms still require further rigorous clinical studies for validation.

conclusionBZYQ modulates Th17 differentiation via the PTEN/AKT-immunometabolic axis in AIT.

Indexed as

Cell DifferentiationDrugs, Chinese HerbalProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseTh17 CellsThyroiditis, AutoimmuneAnimalsFemaleMiceSignal TransductionBuzhong Yiqi decoctionDrugs, Chinese HerbalProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePten protein, mouseautoimmune thyroiditisBuzhong yiqi decoctionhypothyroidismimmunometabolismPTEN/AKT signaling pathwayT helper cell 17

Identifiers

PMID41116264
PMCPMC13635965

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.